Does holding at 1.7 mg for three weeks before escalating reduce reflux?

The particulars: 1.7 mg · three weeks · reflux.

I would like the mechanism, because I want to be able to reason about the cases nobody has written about.

I have tried to reason it out from first principles and got to two contradictory conclusions.

So what is the mechanism, and how well established is it?

three weeks at 1.7 mg is 21 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 1.7 mg back by 21 days. Whether that reduces reflux depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 1.7 mg is 1.7 mg on day 1 and on day 21. A symptom driven by the rate of change has 21 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot reflux against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.

The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.

For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.

Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.

Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.

Four half-lives between steps, minimum. Work it out for your agent.

Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.

The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.

Put another way, escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.

Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.

Slower costs time and nothing else. The ceiling is the same.

Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.

The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.

Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.

The caveat is that titration decisions belong with a clinician who knows what else is on board.

The top of the schedule is not the target. The working dose is.

The initiation step in most schedules is not intended to be therapeutic; it is there to introduce the receptor to the drug.

The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.

Hold rather than escalate while symptoms are active. Always.

Escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.

Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.

Stepping back is a normal adjustment, not a failure.

edited 27 Apr 2026 by e_dziedzic — tightened the wording; no substantive change